I would be shocked if the Board would take $750m or $800m for this cherry. I would think $1B is the starting point. They have Japan ready to take-off and FDA approval any day. They could double their revenues is 2 to 3 years.
20% is only $27 a share. Revenue could easily grow 20% over the next few years. If revenues multiply higher then then we are looking at $45 to $60 a share. I hope management can at least wait for the FDA announcement.